At the intersection of biotechnology, artificial intelligence, and regenerative medicine, our nonprofit research laboratory is focused on redefining the future of human health and longevity. We pursue innovative research in regenerative biology, neuroinflammation, and AI-guided therapeutic discovery to better understand the mechanisms of aging and develop translational solutions for age-related diseases.
By combining advanced molecular science with computational innovation, we strive to accelerate breakthroughs that can extend healthspan, improve quality of life, and unlock new possibilities in precision medicine. Our mission is driven by scientific curiosity, collaborative research, and a commitment to creating accessible biomedical advancements for the benefit of humanity.
Neranjan Tharuka, PhD.
Neranjan is the Founder and Principal Investigator of Athanasia Biolab, where his research focuses on immunology, neuroinflammation, regenerative biology, and AI-guided therapeutic discovery for aging and chronic diseases. His work integrates molecular biology, computational biology, and translational biotechnology to develop innovative strategies in antibody engineering, immune modulation, regenerative medicine, and precision therapeutics.
Neranjan obtained a B.S. in Molecular Biology and Biochemistry from the University of Colombo and an M.S. in Molecular Biology from the University of Hertfordshire. He completed his Ph.D. at Jeju National University, where his research focused on understanding the fish immune system and host-pathogen interactions. He later pursued postdoctoral training at the University of California San Diego, investigating the role of SUMOylation inhibition in T cell-mediated antitumor responses and cancer immunotherapy. He also completed postdoctoral research at the Beckman Research Institute of City of Hope, studying androgen signaling in T cell function and prostate cancer development.
His current research aims to bridge artificial intelligence, immunology, regenerative biology, and therapeutic antibody discovery to accelerate the development of next-generation treatments for cancer, neurodegenerative disorders, inflammatory diseases, and age-related decline.